{
  "api_version": "1",
  "request": {
    "url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Targeted+agent&page=39",
    "query": {
      "intervention": "Targeted agent",
      "page": 39
    },
    "page_size": 10
  },
  "pagination": {
    "page": 39,
    "page_size": 10,
    "total_count": 1322,
    "total_pages": 133,
    "next_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Targeted+agent&page=40&page_size=10",
    "previous_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Targeted+agent&page=38&page_size=10"
  },
  "source": "remote",
  "last_synced_at": "2026-11-04T14:16:14.367Z",
  "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.",
  "notes": [
    "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.",
    "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.",
    "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees."
  ],
  "trials": [
    {
      "nct_id": "NCT04296890",
      "title": "A Study of Mirvetuximab Soravtansine in Platinum-Resistant, Advanced High-Grade Epithelial Ovarian, Primary Peritoneal, or Fallopian Tube Cancers With High Folate Receptor-Alpha Expression",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE3"
      ],
      "conditions": [
        "Epithelial Ovarian Cancer",
        "Peritoneal Cancer",
        "Fallopian Tube Cancer"
      ],
      "interventions": [
        {
          "name": "Mirvetuximab Soravtansine",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "ImmunoGen, Inc.",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "FEMALE",
        "summary": "18 Years and older · Female only"
      },
      "enrollment_count": 106,
      "start_date": "2020-07-23",
      "completion_date": "2022-11-16",
      "has_results": true,
      "last_update_posted_date": "2024-08-07",
      "last_synced_at": "2026-11-04T14:16:14.367Z",
      "location_count": 34,
      "location_summary": "Phoenix, Arizona • Duarte, California • Fresno, California + 29 more",
      "locations": [
        {
          "city": "Phoenix",
          "state": "Arizona"
        },
        {
          "city": "Duarte",
          "state": "California"
        },
        {
          "city": "Fresno",
          "state": "California"
        },
        {
          "city": "Palo Alto",
          "state": "California"
        },
        {
          "city": "San Francisco",
          "state": "California"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT04296890"
    },
    {
      "nct_id": "NCT06859424",
      "title": "A Platform Protocol to Investigate Post-Transplant Cyclophosphamide-Based Graft-Versus-Host Disease Prophylaxis in Patients With Hematologic Malignancies Undergoing Mismatched Unrelated Donor Peripheral Blood Stem Cell Transplantation",
      "overall_status": "RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "AML (Acute Myelogenous Leukemia)",
        "Acute Lymphoid Leukemia (ALL)",
        "Acute Leukemia (Category)",
        "MDS (Myelodysplastic Syndrome)",
        "CML (Chronic Myelogenous Leukemia)",
        "CLL (Chronic Lymphocytic Leukemia)",
        "Prolymphocyctic Leukemia",
        "Chronic Myelomonocytic Leukemia (CMML)",
        "Myeloproliferative Neoplasm (MPN)",
        "Lymphoma",
        "Myelofibrosis"
      ],
      "interventions": [
        {
          "name": "Conditioning Regimen A",
          "type": "DRUG"
        },
        {
          "name": "Conditioning Regimen B",
          "type": "DRUG"
        },
        {
          "name": "Conditioning Regimen C",
          "type": "DRUG"
        },
        {
          "name": "Conditioning Regimen D",
          "type": "DRUG"
        },
        {
          "name": "Conditioning Regimen E",
          "type": "DRUG"
        },
        {
          "name": "Hematopoietic Cell Transplantation",
          "type": "PROCEDURE"
        },
        {
          "name": "PTCy (50 mg/kg D3, D4)",
          "type": "DRUG"
        },
        {
          "name": "PTCy (25 mg/kg D3, D4)",
          "type": "DRUG"
        },
        {
          "name": "Post-transplant Tacrolimus",
          "type": "DRUG"
        },
        {
          "name": "Post-transplant Mycophenolate mofetil",
          "type": "DRUG"
        },
        {
          "name": "Post-transplant Abatacept",
          "type": "DRUG"
        },
        {
          "name": "Post-transplant Ruxolitinib",
          "type": "DRUG"
        },
        {
          "name": "Supportive Care: Growth Factors",
          "type": "DRUG"
        },
        {
          "name": "Supportive Care: Blood Products",
          "type": "PROCEDURE"
        },
        {
          "name": "Supportive Care: Infection Prophylaxis",
          "type": "OTHER"
        },
        {
          "name": "Supportive Care: Intravenous immune globulin (IVIG)",
          "type": "OTHER"
        },
        {
          "name": "Supportive Care: Seizure prophylaxis",
          "type": "DRUG"
        },
        {
          "name": "Supportive Care: Monitoring and management of CRS",
          "type": "OTHER"
        },
        {
          "name": "Supportive Care: Prophylaxis against infections",
          "type": "OTHER"
        },
        {
          "name": "Supportive Care: Prophylaxis against infections",
          "type": "DRUG"
        },
        {
          "name": "Supportive Care: Lipid elevations",
          "type": "OTHER"
        },
        {
          "name": "Study treatment compliance",
          "type": "OTHER"
        },
        {
          "name": "Prohibited Concomitant Therapy",
          "type": "OTHER"
        },
        {
          "name": "Permitted Concomitant Therapy",
          "type": "OTHER"
        }
      ],
      "intervention_types": [
        "DRUG",
        "PROCEDURE",
        "OTHER"
      ],
      "sponsor": "Center for International Blood and Marrow Transplant Research",
      "sponsor_class": "NETWORK",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "66 Years",
        "sex": "ALL",
        "summary": "18 Years to 66 Years"
      },
      "enrollment_count": 358,
      "start_date": "2025-07-25",
      "completion_date": "2028-06",
      "has_results": false,
      "last_update_posted_date": "2026-03-17",
      "last_synced_at": "2026-11-04T14:16:14.367Z",
      "location_count": 13,
      "location_summary": "Birmingham, Alabama • Duarte, California • Palo Alto, California + 10 more",
      "locations": [
        {
          "city": "Birmingham",
          "state": "Alabama"
        },
        {
          "city": "Duarte",
          "state": "California"
        },
        {
          "city": "Palo Alto",
          "state": "California"
        },
        {
          "city": "Miami",
          "state": "Florida"
        },
        {
          "city": "Westwood",
          "state": "Kansas"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT06859424"
    },
    {
      "nct_id": "NCT02154490",
      "title": "Lung-MAP: Biomarker-Targeted Second-Line Therapy in Treating Patients With Recurrent Stage IV Squamous Cell Lung Cancer",
      "overall_status": "COMPLETED",
      "study_type": "OBSERVATIONAL",
      "phases": [],
      "conditions": [
        "Recurrent Squamous Cell Lung Carcinoma",
        "Stage IV Squamous Cell Lung Carcinoma AJCC v7"
      ],
      "interventions": [
        {
          "name": "Docetaxel",
          "type": "DRUG"
        },
        {
          "name": "Durvalumab",
          "type": "BIOLOGICAL"
        },
        {
          "name": "Erlotinib Hydrochloride",
          "type": "DRUG"
        },
        {
          "name": "FGFR Inhibitor AZD4547",
          "type": "DRUG"
        },
        {
          "name": "Ipilimumab",
          "type": "BIOLOGICAL"
        },
        {
          "name": "Laboratory Biomarker Analysis",
          "type": "OTHER"
        },
        {
          "name": "Nivolumab",
          "type": "BIOLOGICAL"
        },
        {
          "name": "Palbociclib",
          "type": "DRUG"
        },
        {
          "name": "Pharmacological Study",
          "type": "OTHER"
        },
        {
          "name": "Rilotumumab",
          "type": "BIOLOGICAL"
        },
        {
          "name": "Talazoparib",
          "type": "DRUG"
        },
        {
          "name": "Taselisib",
          "type": "DRUG"
        },
        {
          "name": "Tremelimumab",
          "type": "BIOLOGICAL"
        }
      ],
      "intervention_types": [
        "DRUG",
        "BIOLOGICAL",
        "OTHER"
      ],
      "sponsor": "SWOG Cancer Research Network",
      "sponsor_class": "NETWORK",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 1864,
      "start_date": "2014-07-08",
      "completion_date": "2022-04-15",
      "has_results": true,
      "last_update_posted_date": "2023-06-01",
      "last_synced_at": "2026-11-04T14:16:14.367Z",
      "location_count": 998,
      "location_summary": "Birmingham, Alabama • Anchorage, Alaska • Fairbanks, Alaska + 639 more",
      "locations": [
        {
          "city": "Birmingham",
          "state": "Alabama"
        },
        {
          "city": "Anchorage",
          "state": "Alaska"
        },
        {
          "city": "Anchorage",
          "state": "Alaska"
        },
        {
          "city": "Anchorage",
          "state": "Alaska"
        },
        {
          "city": "Anchorage",
          "state": "Alaska"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT02154490"
    },
    {
      "nct_id": "NCT00718159",
      "title": "Study of LY573636-sodium in Essential Thrombocythemia and Acute Myeloid Leukemia",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Acute Myeloid Leukemia",
        "Essential Thrombocythemia"
      ],
      "interventions": [
        {
          "name": "LY573636-sodium",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Eli Lilly and Company",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 23,
      "start_date": "2008-08",
      "completion_date": "2011-12",
      "has_results": true,
      "last_update_posted_date": "2019-01-10",
      "last_synced_at": "2026-11-04T14:16:14.367Z",
      "location_count": 5,
      "location_summary": "Los Angeles, California • Aurora, Colorado • Baltimore, Maryland + 2 more",
      "locations": [
        {
          "city": "Los Angeles",
          "state": "California"
        },
        {
          "city": "Aurora",
          "state": "Colorado"
        },
        {
          "city": "Baltimore",
          "state": "Maryland"
        },
        {
          "city": "Las Vegas",
          "state": "Nevada"
        },
        {
          "city": "Houston",
          "state": "Texas"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00718159"
    },
    {
      "nct_id": "NCT04700163",
      "title": "RU Anti-SARS-CoV-2 (COVID-19) mAbs in Healthy Volunteers",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Covid19"
      ],
      "interventions": [
        {
          "name": "C144-LS and C-135-LS",
          "type": "BIOLOGICAL"
        }
      ],
      "intervention_types": [
        "BIOLOGICAL"
      ],
      "sponsor": "Rockefeller University",
      "sponsor_class": "OTHER",
      "healthy_volunteers": true,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 23,
      "start_date": "2021-01-11",
      "completion_date": "2022-02-02",
      "has_results": true,
      "last_update_posted_date": "2025-03-13",
      "last_synced_at": "2026-11-04T14:16:14.367Z",
      "location_count": 1,
      "location_summary": "New York, New York",
      "locations": [
        {
          "city": "New York",
          "state": "New York"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT04700163"
    },
    {
      "nct_id": "NCT06805825",
      "title": "A Study of the c-Kit Specific Antibody-Drug Conjugate NN3201 for Advanced and/or Metastatic Solid Tumors Known to Express c-Kit",
      "overall_status": "RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Gastrointestinal Stromal Tumors",
        "Small-cell Lung Cancer",
        "Adenoid Cystic Carcinoma",
        "Uveal Melanoma",
        "Neuroendocrine Tumors",
        "Chromophobe Renal Cell Carcinoma",
        "Clear Cell Renal Cell Carcinoma"
      ],
      "interventions": [
        {
          "name": "NN3201",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Novelty Nobility, Inc.",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 67,
      "start_date": "2025-02-03",
      "completion_date": "2027-12-31",
      "has_results": false,
      "last_update_posted_date": "2025-09-23",
      "last_synced_at": "2026-11-04T14:16:14.367Z",
      "location_count": 5,
      "location_summary": "Ann Arbor, Michigan • Cleveland, Ohio • Portland, Oregon + 2 more",
      "locations": [
        {
          "city": "Ann Arbor",
          "state": "Michigan"
        },
        {
          "city": "Cleveland",
          "state": "Ohio"
        },
        {
          "city": "Portland",
          "state": "Oregon"
        },
        {
          "city": "Houston",
          "state": "Texas"
        },
        {
          "city": "Fairfax",
          "state": "Virginia"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT06805825"
    },
    {
      "nct_id": "NCT03516708",
      "title": "Epacadostat (INCB024360) Added to Preoperative Chemoradiation in Patients With Locally Advanced Rectal Cancer",
      "overall_status": "RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1",
        "PHASE2"
      ],
      "conditions": [
        "Rectal Cancer"
      ],
      "interventions": [
        {
          "name": "Epacadostat",
          "type": "DRUG"
        },
        {
          "name": "Short-course radiation therapy",
          "type": "RADIATION"
        },
        {
          "name": "CAPOX chemotherapy",
          "type": "DRUG"
        },
        {
          "name": "FOLFOX chemotherapy",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG",
        "RADIATION"
      ],
      "sponsor": "Washington University School of Medicine",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 49,
      "start_date": "2020-01-06",
      "completion_date": "2030-08-12",
      "has_results": false,
      "last_update_posted_date": "2026-02-11",
      "last_synced_at": "2026-11-04T14:16:14.367Z",
      "location_count": 4,
      "location_summary": "Orange, California • Boston, Massachusetts • Detroit, Michigan + 1 more",
      "locations": [
        {
          "city": "Orange",
          "state": "California"
        },
        {
          "city": "Boston",
          "state": "Massachusetts"
        },
        {
          "city": "Detroit",
          "state": "Michigan"
        },
        {
          "city": "St Louis",
          "state": "Missouri"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT03516708"
    },
    {
      "nct_id": "NCT03455374",
      "title": "Diamondback in Peripheral Vascular Disease",
      "overall_status": "TERMINATED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "NA"
      ],
      "conditions": [
        "Peripheral Vascular Diseases",
        "Critical Limb Ischemia"
      ],
      "interventions": [
        {
          "name": "Treatment with CSI atherectomy device",
          "type": "DEVICE"
        }
      ],
      "intervention_types": [
        "DEVICE"
      ],
      "sponsor": "Arkansas Heart Hospital",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 10,
      "start_date": "2017-08-08",
      "completion_date": "2019-05-13",
      "has_results": false,
      "last_update_posted_date": "2019-06-27",
      "last_synced_at": "2026-11-04T14:16:14.367Z",
      "location_count": 2,
      "location_summary": "Little Rock, Arkansas",
      "locations": [
        {
          "city": "Little Rock",
          "state": "Arkansas"
        },
        {
          "city": "Little Rock",
          "state": "Arkansas"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT03455374"
    },
    {
      "nct_id": "NCT03408873",
      "title": "CAE Plus LAI in Individuals With Bipolar Disorder at Risk for Treatment Non-adherence (BD-CAEL)",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE4"
      ],
      "conditions": [
        "Bipolar Disorder",
        "Medication Adherence",
        "Medication Non Adherence"
      ],
      "interventions": [
        {
          "name": "Abilify Maintena",
          "type": "DRUG"
        },
        {
          "name": "Customized Adherence Enhancement (CAE)",
          "type": "BEHAVIORAL"
        }
      ],
      "intervention_types": [
        "DRUG",
        "BEHAVIORAL"
      ],
      "sponsor": "Martha Sajatovic",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 30,
      "start_date": "2018-04-01",
      "completion_date": "2020-05-06",
      "has_results": true,
      "last_update_posted_date": "2022-02-17",
      "last_synced_at": "2026-11-04T14:16:14.367Z",
      "location_count": 1,
      "location_summary": "Cleveland, Ohio",
      "locations": [
        {
          "city": "Cleveland",
          "state": "Ohio"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT03408873"
    },
    {
      "nct_id": "NCT05241873",
      "title": "(Concerto) Study of BLU-451 in Advanced Cancers With EGFR Exon 20 Insertion Mutations",
      "overall_status": "TERMINATED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Lung Neoplasm Malignant",
        "Carcinoma, Non-Small-Cell Lung",
        "Respiratory Tract Neoplasms",
        "Neoplasms",
        "Neoplasms by Site",
        "Lung Diseases",
        "Respiratory Tract Disease",
        "Carcinoma, Bronchogenic",
        "Bronchial Neoplasms",
        "Adenocarcinoma",
        "Carcinoma",
        "Neoplasms by Histologic Type",
        "EGFR Exon 20 Mutation",
        "EGFR Exon 20 Insertion Mutation",
        "EGFR Activating Mutation",
        "Antineoplastic Agents",
        "Metastatic Lung Cancer",
        "Brain Metastases",
        "EGFR-mutated NSCLC",
        "EGFR Atypical Mutations, Including G719X and L861Q"
      ],
      "interventions": [
        {
          "name": "BLU-451",
          "type": "DRUG"
        },
        {
          "name": "Carboplatin",
          "type": "DRUG"
        },
        {
          "name": "Pemetrexed",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Blueprint Medicines Corporation",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 103,
      "start_date": "2022-03-04",
      "completion_date": "2024-07-31",
      "has_results": false,
      "last_update_posted_date": "2025-02-10",
      "last_synced_at": "2026-11-04T14:16:14.367Z",
      "location_count": 13,
      "location_summary": "Duarte, California • Los Angeles, California • Aurora, Colorado + 8 more",
      "locations": [
        {
          "city": "Duarte",
          "state": "California"
        },
        {
          "city": "Los Angeles",
          "state": "California"
        },
        {
          "city": "Aurora",
          "state": "Colorado"
        },
        {
          "city": "Washington D.C.",
          "state": "District of Columbia"
        },
        {
          "city": "Chicago",
          "state": "Illinois"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT05241873"
    }
  ]
}